Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2018-05-15 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
第八届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding decisions made at a board meeting, including approval of contracts and the proposal to convene the annual shareholders' meeting. It includes voting results and references to related announcements. The content focuses on board/management decisions and meeting resolutions rather than financial results, audit information, or shareholder voting outcomes. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2018-05-15 Chinese
2017年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as "江苏四环生物股份有限公司 2017 年年度报告摘要" which translates to "Jiangsu Sihuan Biological Co., Ltd. 2017 Annual Report Summary." It contains detailed financial data for the year 2017, including revenue, net profit, earnings per share, and shareholder information. The document is about 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The content includes comprehensive financial metrics, business overview, industry analysis, and shareholder structure, which are typical components of an Annual Report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2017
2018-04-27 Chinese
2017年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled '2017 年度监事会工作报告' which translates to '2017 Supervisory Board Work Report'. It details the supervisory board's activities during the 2017 fiscal year, including meetings held, resolutions passed, and opinions on company operations, financial status, internal controls, and fund usage. The content is a formal report from the supervisory board on their oversight and review of company governance and financial matters for the year 2017. It is not an announcement or a brief summary but a substantive report on governance and oversight activities. This fits the category of an Audit Report / Information (AR), as it includes audit-related supervisory opinions and internal control evaluations, but is not a full Annual Report (10-K) or other categories like Management Reports or Governance Information. The document length is 1558 characters, which is short but the content is a detailed supervisory board report, not just an announcement. Therefore, the best classification is AR with high confidence. FY 2017
2018-04-27 Chinese
关于2017年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Sihuan Bio about the 2017 annual asset impairment provision. It details the amount of impairment provision made, the accounting basis, and the impact on profits. It includes board and independent director opinions and supervisory board review. The document is relatively short (1625 characters) and is an announcement of a specific accounting action rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or regulatory compliance filing. The content fits best with a Regulatory Filing (RNS) as it is a specific disclosure about asset impairment provisions without being a full report or a meeting material. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2018-04-27 Chinese
2017年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2017年度董事会工作报告" which translates to "2017 Annual Board of Directors Work Report." It details the activities, meetings, and resolutions of the board of directors throughout the year 2017, including information about board composition, committees, and governance practices. It also includes financial performance summaries but does not present full financial statements or comprehensive annual financial data. The document focuses on the board's work and governance rather than being a full annual report or audit report. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements related to the company's board and senior management activities.
2018-04-27 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It details the adoption of new accounting standards issued by the Ministry of Finance and their impact on the company's financial statements. The document includes opinions from the board of directors, independent directors, and the supervisory board, confirming the reasonableness and compliance of the policy changes. The document is relatively short (1862 characters) and does not contain full financial statements or comprehensive financial data. It is not a full annual or interim report but rather a regulatory announcement about accounting policy changes. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure without substantive financial statements.
2018-04-27 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.